December 6, 2023
Dermavant Announces Positive Results from Phase 4 ...
Read More
October 20, 2023
Dermavant Presents Positive Results from Phase 4 O ...
Read More
October 16, 2023
Dermavant to Present New Positive Data from Phase ...
Read More
October 13, 2023
Dermavant Champions a Culture that Earns Three Bes ...
Read More
October 12, 2023
Dermavant Announces New Positive Pruritus Data for ...
Read More
October 6, 2023
Dermavant to Present Data from ADORING 1 and 2 Piv ...
Read More
October 5, 2023
Dermavant Appoints John Darden as New Head of Mark ...
Read More
May 16, 2023
Dermavant Reports Positive Topline Results from AD ...
Read More
March 15, 2023
Dermavant Reports Positive Topline Results from AD ...
Read More
March 10, 2023
Dermavant to Present Data from Multiple Studies of ...
Read More
February 13, 2023
Dermavant Completes Enrollment of Two Phase 3 Clin ...
Read More
January 12, 2023
Dermavant to Present Data from Multiple Studies of ...
Read More
October 13, 2022
Dermavant to Present Data from Multiple Clinical T ...
Read More
March 25, 2022
Dermavant Showcases New Long-Term Durability and T ...
Read More
March 11, 2022
Dermavant to Present New Data from the Phase 3 PSO ...
Read More
March 8, 2022
Dermavant Appoints Nancy Beesley to its Board of D ...
Read More
January 15, 2022
Dermavant Presents New Patient Satisfaction Data f ...
Read More
January 7, 2022
Dermavant to Present New Data from Phase 3 PSOARIN ...
Read More
December 9, 2021
Dermavant Announces Publication of PSOARING 1 ...
Read More
December 9, 2021
The New England Journal of Medicine: Phase 3 Trial ...
Read More
